In patients with heart failure and reduced left ventricular ejection fraction (LVEF), secondary (functional) mitral regurgitation, in which the mitral valve leaflets and chordae are essentially normal, is the result of functional and structural alterations of the left ventricle (LV). Severe secondary mitral regurgitation (MR) is a predictor of poor clinical outcomes in this patient population due to more hospitalisations for heart failure (HF), poor quality of life and shortened survival times. [1] [2] [3] [4] While guideline-directed medical therapy (GDMT) may have an impact on LV function, symptomatology and functional MR severity, there has been no data to show that surgical treatment of secondary MR is associated with lower incidence of death or hospitalisation. that although the MitraClip was safer than surgical mitral valve repair, the transcatheter option was not as effective in reducing MR severity among the study group, who mostly had primary MR. 6 Prospective clinical trials with hard clinical outcomes on the beneficial effect on secondary MR of enhancing GDMT with percutaneous transcatheter mitral valve repair had not been shown until now. 
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A Tale of Two Trials

Recruitment
What is evident is that there were clear differences between the two trials regarding patient selection, medical treatment optimisation, the severity parameters of MR and the setting of the LV volume index parameters. Some of this is due to differences between European and American guidelines. In addition, these differences were only found in a post-hoc analysis and are therefore subject to inherent limitations.
Nevertheless, in the MITRA-FR trial, the majority of patients had an average effective regurgitant orifice area (EROA) of 30 mm 2 which suggests moderate MR rather than severe, whereas in the COAPT trial, the majority of patients had an average EROA of 40 mm 2 The highly stringent patient selectivity in the COAPT trial is the obvious difference between the two trials. The MITRA-FR trial was designed to be more true to life in terms of medical therapy and optimisation.
The rates of drug use and medication titration throughout the MITRA-FR trial course were not tracked, and although these were guideline directed, they may not have been guideline optimised.
Yet the story does not end here -the percentage of drugs used in MITRA-FR was higher than COAPT even if dose optimisation was not checked by a selection committee. In addition, although there were a significant number of HF hospitalisations in the COAPT trial, the doses of medications were not changed significantly.
Size of Study and Study Design
The number of patients and follow-up were different between the two trials. The MITRA-FR trial enrolled about 300 patients, 150 in each arm;
and the COAPT trial enrolled about 600, 300 in each arm. Perhaps an effect size may not have been seen in MITRA-FR that was seen in COAPT. Although hospitalisations differed early on between the two patient groups in the COAPT trial (partly due to a more rigorous medical arm), mortality did not differentiate until the second year. The follow-up period for MITRA-FR was only 1 year. Perhaps the positive nature of COAPT could be partially down to better design, probably due to more accessible funding.
Technical Success and Procedural Safety
Technical success and procedural safety may be different between the two trials. Residual MR class ≥3+ was higher post-clip for MITRA-FR compared with COAPT, both acutely (9% versus 5%) and at 12 months (17% versus 5%); procedural complications -although low and improving with current experience -were higher in MITRA-FR than in COAPT (14.6% versus 8.5%), and residual MR class ≥3+ was higher post-clip for MITRA-FR compared with COAPT, both acutely (9% versus 5%) and at 12 months (17% versus 5%). [7] [8] It is important to note that there was no common core lab evaluation of both trials. More patients in COAPT had more than one clip implanted compared with patients in the MITRA-FR trial. This raises questions over the use of 3D imaging during the procedure. 3D
imaging is better than 2D imaging at identifying location of jets, perpendicularity, post-clip leak and mitral valve area. For procedural complications, there was about a twofold higher rate of device implant failure, cardiogenic shock, stroke and tamponade in MITRA-FR compared with COAPT, which may be due to different patient populations or patients who are at different stages of the disease.
These are significant issues that are likely to be associated with negative primary outcomes.
Selecting Patients Who Will Benefit From MitraClip
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Why Did COAPT Win While MITRA-FR Failed?
The Future
There are still some unanswered questions from these trials. Some of these are based on COAPT subsets to better identify patients who will benefit from the intervention, such as effects based on patients with or without frailty, medical changes during the trial period, postprocedural high gradient and more.
How do we improve the medical and procedural treatment for those in MITRA-FR who are outside the range of COAPT? Will other therapies,such as rings and valve replacement, provide better outcomes, and for which patients? These are questions worthy of consideration and we will undoubtedly see more data in the coming years. At this time, both trials provide guidance we may use to get maximal results in practice, and create opportunities for other mitral valve therapies to also work in the COAPT and MITRA-FR patient spaces. It is important to remember that MR and HF are a vast frontier for us to explore and these two trials are just the beginning. We have neither won nor lost at this time -we are still gathering information about this important disease process, and our patients will look to us for answers in the years ahead.
